Prostate Cancer

January 31, 2022 Benign prostatic hyperplasia or BPH is a natural enlargement of the prostate. Fifty percent of men in their 50s will have this condition, along with 80% of men in their 80s. A frequent urge to urinate is a common side effect, but more serious problems, like blood in the urine and bladder stones can be damaging to a man's health. In today's Healthy Living, Andrea Ludema has details on a treatment proving to eliminate these issues for good.

[unable to retrieve full-text content] Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities    The Lancet

[unable to retrieve full-text content] No, blocking male hormones is not a legitimate treatment for COVID-19    WGHP FOX8 Greensboro

Introduction Prostate cancer (PCa) is the most common noncutaneous cancer in men in the United States. Approximately 191,930 men will be diagnosed and 33,330 men will die from PCa in 2020. 1 With the introduction of widespread prostate-specific antigen (PSA) screening, most men are diagnosed at the localized PCa stages. Several well-established treatment options, such as radical prostatectomy, radiation therapy, and whole-gland cryotherapy, are available for localized PCa. Although these treatment modalities are highly effective in providing a cure at the localized stage, they are often associated with debilitating adverse effects (AEs) such as erectile dysfunction and urinary incontinence. As a result, patients often delay or defer treatment of their PCa altogether. In the past decade, active surveillance (AS) has increased for low- and very low-risk PCa, which has reduced overtreatment and sequelae of definitive treatment. However, as noted in the PROTECT trial, approximately 50% of

Background Adenoid cystic carcinoma (ACC) is a rare, distinctive salivary gland malignant neoplasm infrequently arising as a primary tumor in the lung. 1 ACC often arises in the trachea and main bronchus. Morphologically, this subset of primary pulmonary carcinoma is histologically indistinguishable from ACC arising from other sites. ACC can have three architectural growth patterns: cribriform, tubular, and solid, with a cribriform pattern being the most common type. The solid variant of ACC is a histologically distinct subtype that has been associated with an unfavorable clinical course. 2,3 We report on a case of a solid tracheal variant of ACC that has a striking basaloid appearance. We performed a clinicopathological, immunophenotypic, and molecular analysis to delineate the characteristic features of this rare subtype. We highlight the need to recognize ACC in its solid form, discuss the differential diagnosis, and emphasize the need to establish a correct diagnosis for approp

When Anna Heslin started to experience an 'incredible burning pain' down below, she put it down to a bikini wax. The 44-year-old went to see a dermatologist who was convinced that Ann had contracted a sexually transmitted infection (STI). But after her tests came back negative in January 2021, Ann was put on an aggressive course of antibiotics and steroid cream. She had discovered that two ulcers had formed on her labia and said nothing was working to help the pain and that it was progressively getting worse and worse. Desperate for a solution, Ann, who lives in Louisiana, said she went for a biopsy, which tragically revealed she had squamous cell carcinoma. Squamous cell carcinoma is a common form of skin cancer, and is the same illness that killed Ann's father in 2010. It can occur anywhere in the body and develops in the cells that make up the middle and outer layers of the skin. In most cases it is oft

Liang Deng, 1 Chao Li, 1 Qiangrong He, 1 Chenghui Huang, 2 Qian Chen, 3 Shengwang Zhang, 4 Long Wang, 1 Yu Gan, 5 Zhi Long 1 1 Andrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China; 2 Department of Medical Oncology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China; 3 Department of Pathology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China; 4 Department of Radiation Oncology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China; 5 Department of Urology, Xiangya Hospital of Central South University, Changsha, 410008, People's Republic of China Correspondence: Yu Gan, Department of Urology, Xiangya Hospital of Central South University, 87 Xiang Road, Changsha, Hunan, People's Republic of China, Tel +86 15111140